Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
MyoKardia was a clinical-stage biopharmaceutical company dedicated to pioneering a precision medicine approach for treating serious and often neglected cardiovascular diseases. Founded in 2012, MyoKardia's core mission was to develop targeted therapies that address the underlying genetic and biochemical drivers of conditions such as hypertrophic cardiomyopathy (HCM). Their lead therapeutic candidate, mavacamten (marketed as Camzyos®), is a first-in-class allosteric modulator of cardiac myosin, specifically designed to reduce the excessive heart muscle contraction characteristic of HCM. In a landmark move for its cardiovascular franchise, Bristol Myers Squibb (BMS) acquired MyoKardia in November 2020 for $13.1 billion, integrating MyoKardia's innovative pipeline, including mavacamten, and specialized expertise into BMS.
Served as the primary center for MyoKardia's research and development activities, clinical operations, and corporate administration, focusing on the discovery and advancement of targeted cardiovascular therapies.
The headquarters was likely located within a modern life sciences campus, equipped with specialized laboratory facilities necessary for biopharmaceutical research and drug development, alongside collaborative office environments.
MyoKardia's work culture was characterized by a strong emphasis on scientific innovation, a patient-first approach to drug development, and a dynamic, fast-paced environment typical of a pioneering biotechnology firm. Collaboration and scientific excellence were key tenets.
This headquarters was the birthplace of significant advancements in cardiology, most notably the development of mavacamten, a transformative treatment for hypertrophic cardiomyopathy. It symbolized the company's leadership in precision medicine for heart conditions.
Before being acquired by Bristol Myers Squibb, MyoKardia's direct operational footprint was largely concentrated in the United States, centered on its research, clinical development, and corporate activities. While its R&D and corporate base was in California, its clinical trials for promising drug candidates like mavacamten involved investigative sites across North America, Europe, and other regions to ensure comprehensive and diverse patient data. Since the acquisition, MyoKardia's innovations, especially its flagship product Camzyos (mavacamten), are being developed, manufactured, and commercialized on a global scale through Bristol Myers Squibb's extensive worldwide infrastructure, making these therapies accessible to patients in numerous countries.
1000 Sierra Point Parkway
Brisbane
California
USA
Address: N/A
MyoKardia's strategy involved focusing its primary operational infrastructure and talent at a single main site to foster close collaboration and efficiency in its drug development efforts.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, MyoKardia' leadership includes:
MyoKardia has been backed by several prominent investors over the years, including:
Following the acquisition by Bristol Myers Squibb in November 2020, MyoKardia ceased to operate as an independent public company. Its executive team members largely transitioned to roles within Bristol Myers Squibb, pursued new opportunities, or departed after assisting with the integration. Consequently, specific 'MyoKardia' executive hires or exits in the last 12-24 months are not applicable as it is no longer a standalone entity. The most significant executive 'news' was the acquisition itself and the subsequent changes in leadership structure as MyoKardia's assets and personnel were integrated into BMS.
Discover the tools MyoKardia uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Prior to its acquisition by Bristol Myers Squibb, MyoKardia, Inc. likely utilized standard corporate email formats common in the biopharmaceutical industry. These email formats are no longer in active use for MyoKardia as an independent entity, as communications are now handled through Bristol Myers Squibb channels. Common historical patterns included combinations of first name, last name, and initial.
Likely formats included [first_initial][last]@myokardia.com (e.g., jdoe@myokardia.com) or [first].[last]@myokardia.com (e.g., jane.doe@myokardia.com).
Format
example@myokardia.com
Example
0 (domain is no longer independently active; emails would not be delivered)%
Success rate
Bristol Myers Squibb • November 17, 2020
Bristol Myers Squibb announced the successful completion of its acquisition of MyoKardia for $13.1 billion. This strategic acquisition significantly enhances BMS's cardiovascular portfolio with the addition of mavacamten, a potential first-in-class medicine for obstructive hypertrophic cardiomyopathy....more
Bristol Myers Squibb • April 28, 2022
The U.S. Food and Drug Administration (FDA) approved CAMZYOS™ (mavacamten), a therapy originally developed by MyoKardia, for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM). This approval marked a major success for the science MyoKardia advanced....more
MyoKardia / BMS • October 5, 2020
MyoKardia announced it had entered into a definitive agreement to be acquired by Bristol Myers Squibb for $225.00 per share in cash, an aggregate value of $13.1 billion. The deal was aimed at leveraging BMS's resources to maximize the potential of mavacamten and MyoKardia's pipeline....more
MyoKardia (Archived News) • May 29, 2019
MyoKardia reported positive top-line results from its pivotal Phase 3 EXPLORER-HCM clinical trial evaluating mavacamten in patients with obstructive hypertrophic cardiomyopathy. The study met its primary endpoint, demonstrating statistically significant and clinically meaningful improvements in symptoms and cardiac function....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including MyoKardia, are just a search away.